Interferon-Alpha clinical trials

MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera

This study compares a new drug, ruxolitinib, with standard treatments (hydroxycarbamide or interferon) for people with high-risk Polycythaemia Vera. It aims to see which treatment works best as a first approach.